Biopharma’s caution today could put future growth at risk, ZS research finds
EVANSTON, Ill., Nov. 16, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
Biopharma’s caution today could put future growth at risk, ZS research finds
PR Newswire
EVANSTON, Ill., Nov. 16, 2026
New ZS Impact Institute™ research finds biopharma leaders expect continued growth while making decisions that could weaken the innovation needed to sustain it.
EVANSTON, Ill., Nov. 16, 2026 /PRNewswire/ — Biopharma is confident it will grow through 2035, yet new research from the ZS Impact Institute suggests getting there is far less certain.
Nearly nine in 10 biopharma executives and industry experts expect branded drug revenue to grow in real terms through 2035. That confidence comes despite looming patent expirations and most favored nation (MFN)-style U.S. pricing pressure, which 80% of respondents expect to remain at least moderately significant. Delivering that growth will require the industry to find new sources of revenue, even as it makes safer bets on where that future growth will come from.
The research finds challenges emerging on both sides of the equation. Two-thirds of respondents expect treating more patients to help offset lower U.S. prices. Separately, only 44% expect the U.S. to shift toward higher patient volumes at lower prices. Meanwhile, companies are investing later in drug development and expect more of their future pipelines to come from outside their own labs, including China.
“Biopharma can’t solve its pricing challenge separately from its innovation challenge,” said Jon Roffman, ZS principal and lead contributor to the report. “Lower prices put pressure on companies to reach more patients and bring more medicines to market. But if the industry simultaneously takes less early-stage risk, it could weaken the pipeline that future growth depends on. The companies best positioned for the next decade will plan for both at once.”
The pipeline behind future growth is changing
The research points to three shifts reshaping where future medicines may come from:
- Large pharma expects to build less of its pipeline on the inside: Respondents project internally developed assets to fall from 40% today to 32% by 2035, increasing reliance on biotech companies and other external developers.
- Investment may move toward later-stage assets: Seventy-nine percent of respondents say biotech companies will need stronger clinical and commercial evidence to raise money, while investment is expected to shift toward drugs that have reached phase 2 and beyond. While this reduces development risk for individual companies, it leaves a fundamental question: Who funds the early science needed to create those later-stage opportunities?
- China-origin innovation may become more important, and potentially harder to access: Fifty-seven percent of respondents see China-origin innovation becoming essential or dominant in competitive pipelines by 2035. Meanwhile, 48% expect policy and reimbursement pressures to lead Western pharma to limit licensing of China-origin assets.
The report’s analysis suggests that these shifts could create a mismatch between where biopharma expects to find future medicines and where capital is available to create them. As companies rely more on external innovation, a pullback from early-stage investment could leave fewer assets available to license or acquire, while greater dependence on China could introduce additional geopolitical and policy risks.
Download Biopharma Outlook 2035 to explore how biopharma leaders can adapt to changing growth economics while building more resilient pipelines through 2035.
The ZS Impact Institute surveyed 305 biopharma executives and external industry experts and conducted in-depth interviews with a sample of respondents. In this report, “China-origin innovation” refers to innovation discovered, developed, funded or primarily advanced through China-linked organizations, infrastructure or capital.
About the ZS Impact Institute
The ZS Impact Institute delivers data-driven foresight and decision-ready guidance for leaders navigating disruption. By combining proprietary research with real-world experience, the Institute helps executives understand what’s changing, why it matters and what to do next, so they can turn ideas into results that improve life and how we live it.
About ZS
ZS is a management consulting and technology firm that partners with companies to improve life and how we live it. We transform ideas into impact by bringing together data, science, technology and human ingenuity to deliver better outcomes for all. Founded in 1983, ZS has more than 15,000 employees in over 40 offices worldwide. To learn more, visit ZS or follow ZS on LinkedIn.
Media contact
Maryam Ayromlou
Ruder Finn
ZS-RFMedia@ruderfinn.com
+1 703 474 5685
View original content to download multimedia:https://www.prnewswire.com/news-releases/biopharmas-caution-today-could-put-future-growth-at-risk-zs-research-finds-302940423.html
SOURCE ZS
